Detail

Basic Information Clinical Results Relationship Graph

Basic Information

Gene symbol	CD19	Synonyms	B4, CVID3	Type of gene	protein-coding
Chromosome	16	Map location	16p11.2	dbXrefs	Entrez:930 MIM:107265 HGNC:HGNC:1633 Ensembl:ENSG00000177455 AllianceGenome:HGNC:1633
Description	CD19 molecule

GTO ID	GTC0342
Trial ID	NCT02975687
Disease	Acute Lymphoblastic Leukemia
Altered gene	CD19
Therapeutic/Target gene	Target gene
Therapy	CAR-T cell
Treatment	CNCT19\|inaticabtagene autoleucel
Location approved	China
Generation	2nd
Phase	Phase1
Recruitment status	Completed
Title	CD19 CAR T Cells in Patients With Resistant or Refractory CD19+ Acute Lymphoblastic Leukemia
Year	2016
Country	China
Company sponsor	Institute of Hematology & Blood Diseases Hospital
Other ID(s)	XH-CD19CART-001\|HY001001

Vector information

Vector	lentivirus
Construct	pCDH-HI19α-4-1BB/CD3ζ-CAR
Transgene/Inserted gene	Anti-CD19 scFv combined to human 4-1BB/CD3-ζ costimulatory signaling components
Vector production method	The CD19 CAR T cells were produced by Juventas Cell Therapy Ltd (Product ID: CNCT19). Anti-CD19 scFv combined to human 4-1BB/CD3-ζ costimulatory signaling components were cloned into a lentiviral backbone to obtain lentiviral vectors pCDH-HI19α-4-1BB/CD3ζ-CAR.

Clinical Result

Cohort 1

Administration route	intravenous infusion
Dosage	5E6~E7 cells/kg, 0% on day 0, 30% on day 1 and 60% on day 2
Donor type	Autologous
Pts	20
Age	Adult, Older_Adult
Lymph depletion	Yes
Outcome	18/20(CR); 2/20(PD)
Adverse reactions	9/20(cytokine release syndrome); 8/20(CAR T cell-related encephalopathy syndrome); 4/20(infection)
References	PMID: 32894185

Relationship Graph

Overview of Knowledge Graph